Skip to main content
SpringerLink
Log in

Immunostimulatory DNA - Dynavax

AIC, Amb a 1 Immunostimulatory Conjugate, HBV-ISS, ISS 1018, ISS DNA, ISS DNA — Dynavax, ISS1, ISS2

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Notes

  1. This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.

References

  1. Dynavax Technologies Corporation. Dynavax presents Phase II results for ragweed immunotherapy (AIC) at American Academy of Allergy, Asthma and Immunology (AAAAI)Meeting. Media Release: [2 pages], 20 Mar 2001. Available from URL: http://www.dynavax.com

    Google Scholar 

  2. Dynavax announce positive hepatitis B prophylaxis data. Wall Street Journal: [2 pages], 18 Dec 2001. Available from URL: http://wsj.com

    Google Scholar 

  3. Dynavax Technologies Corp. Dynavax demonstrates ability of immunostimulatory DNA sequences to inhibit symptoms of allergic asthma in animal model. EurekAlert [online]: [2 pages], 15 Dec 1998: Available fromURL: http://www.eurekalert.or

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Immunostimulatory DNA - Dynavax. Drugs R&D 3, 193–196 (2002). https://doi.org/10.2165/00126839-200203030-00011

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200203030-00011

Keywords

Search

Navigation